anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will be recruited from outpatient cardiology clinics and inpatient cardiology wards at twenty cardiac centers in 17 countries spread across all African regions. They all belong to the Africa Heart Rhythm Association (AFHRA) network, and participants are included if they have a preexcitation (WPW) pattern on an ECG. A written consent will be obtained, and an ethical clearance from each center will be obtained from their institution. The exclusion criteria were a lack of consent.
Patients receive tocilizumab IV every 12 hours for up to 3 doses in the absence of disease progression or unacceptable toxicity. Patients also receive standard of care.
Use of a cosmetic and/or dermo-cosmetic containing herbal extract base of Pyrus malus for the preparation of a cosmetic product to correct, maintain and improve the moisture level of the skin. An independent claim is included for a cosmetic or dermo-cosmetic composition, to correct, maintain and/or improve the moisture level of the skin, comprises a herbal extract of Pyrus Malus. ACTIVITY : Dermatological. MECHANISM OF ACTION : Aquaporin-3 inhibitor. The inhibitory effect on aquaporin-3 was tested in nasal epithelium keratinocyte cells using biological assay. The result showed that the inhibitory effect of herbal extract was 172% while that of control was 100%.
G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr will be administered for five consecutive days. Four such cycles at 3 monthly intervals will be administered.
The design of the intervention requires incorporating content that involves intrapersonal (benefits of active transportation and safety on the way to school), interpersonal (family safety), organizational, community, physical-environmental, and political (safety, infrastructure, quality) factors. It will consist of weekly sessions of 60 to 90 minutes each for 16 weeks. The complete program has a duration of 4 months, during school hours in the subject of Physical Education, and on the premises of each establishment. The contents to be worked on will be organized in a Didactic Unit and will include the presentation of graphic and audiovisual material and practical contents. Each session will be designed based on the results of PHASE 1 of the study, following the recommendations of active transport interventions in schoolchildren , and the material available from the PACO Project.
Participants in this group received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants were re-randomized into 2 groups: participants in one receiving an additional dose of RSVPreF3 OA vaccine before Season 2; participants in the other receiving a dose of placebo before Season 2.
PURPOSE:To obtain a long acting preparation consisting of a water soluble medicine active ingredient and mixture of lipid substances having different melting points and having both of rapid release and sustained release together regardless of single preparation. CONSTITUTION:The sustained release preparation consisting of 1 pts.wt. water soluble medicine active ingredient and 1-10 pts.wt. mixture containing two or more kind of lipid substances having different melting points, preferably lipid substance having >=60 deg.C high melting point and lipid substance of low melting point having melting point >=10 deg.C lower than that of the former at an amount of 0.05-1.0 pts.wt., especially 0.2-0.5 pts.wt. latter based on 1 pts.wt. former. The above-mentioned preparation is prepared by suspending or melting the medicine active ingredient into a mixed melt liquid of lipid substances, spraying the suspension or melt while maintaining temperature of solidifying point or above and cooling the suspension or melt to form a granule and heat-treating the granule at the temperature between melting points of both lipid substances and has structure composed of exposed main drug layer, smooth lipid substance layer and matrix core of the main drug and lipid substances.
Postprandial lipid and hormonal responses are being investigated in up to 15 individuals. Participants are their own control in a single-blind, placebo-controlled, crossover design. Participants are admitted after an overnight fast. Participants will consume a high-fat drink (50g of fat) along with either oral placebo, olanzapine (10mg) or olanzapine (10mg) plus bromocriptine (5mg). Study visits occur 2-4 weeks apart with the three treatments applied in random order. Blood samples will be taken at baseline and regular intervals after the treatments for up to 8 hours to measure glucose, insulin, triglycerides, fatty acids and other hormones/metabolites.
FIELD: medicine, narcology. SUBSTANCE: at the first stage of treatment an esperal is introduced per 0.25 g twice daily for 5-10 days. During the second stage a psychosuggestive impact is conducted by imperative suggestion in awake state of a patient. At the third stage a herb infusion is introduced prepared by simple mixing of the following herbs, such as leonorus, mint, wormwood and asarum at the ratio of 1.0:0.5:0.3:0.2, correspondingly followed by a fractional water extraction of components. Herb infusion should be introduced per 100 ml thrice daily 20 minutes before meals for the period of 21 days. EFFECT: higher efficiency of the method, decreased terms of therapy course.
Background Whether connectome mapping of structural and functional connectivity across the brain could be used to predict patterns of atrophy progression in patients with mild Parkinson disease (PD) has not been well studied. Purpose To assess the structural and functional connectivity of brain regions in healthy controls and its relationship with the spread of gray matter (GM) atrophy in patients with mild PD. Materials and Methods This prospective study included participants with mild PD and controls recruited from a single center between January 2012 and December 2023. Participants with PD underwent three-dimensional T1-weighted brain MRI, and the extent of regional GM atrophy was determined at baseline and every year for 3 years. The structural and functional brain connectome was constructed using diffusion tensor imaging and resting-state functional MRI in healthy controls. Disease exposure (DE) indexes-indexes of the pathology of each brain region-were defined as a function of the structural or functional connectivity of all the connected regions in the healthy connectome and the severity of atrophy of the connected regions in participants with PD. Partial correlations were tested between structural and functional DE indexes of each GM region at 1- or 2-year follow-up and atrophy progression at 2- or 3-year follow-up. Prediction models of atrophy at 2- or 3-year follow-up were constructed using exhaustive feature selection. Results A total of 86 participants with mild PD (mean age at MRI, 60 years ± 8 [SD]; 48 male) and 60 healthy controls (mean age at MRI, 62 years ± 9; 31 female) were included. DE indexes at 1 and 2 years were correlated with atrophy at 2 and 3 years (r range, 0.22-0.33; P value range, .002-.04). Models including DE indexes predicted GM atrophy accumulation over 3 years in the right caudate nucleus and some frontal, parietal, and temporal brain regions (R2 range, 0.40-0.61; all P < .001). Conclusion The structural and functional organization of the brain connectome plays a role in atrophy progression in the early stages of PD. © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Yamada in this issue.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice.

###  Heart Failure Post-Myocardial Infarction

In EPHESUS, safety was evaluated in 3307 patients treated with eplerenone and 3301 placebo-treated patients. The overall incidence of adverse events reported with eplerenone (78.9%) was similar to placebo (79.5%). Adverse events occurred at a similar rate regardless of age, gender, or race. Patients discontinued treatment due to an adverse event at similar rates in either treatment group (4.4% eplerenone vs. 4.3% placebo), with the most common reasons for discontinuation being hyperkalemia, MI, and abnormal renal function.

Adverse reactions that occurred more frequently in patients treated with eplerenone than placebo were hyperkalemia (3.4% vs. 2.0%) and increased creatinine (2.4% vs. 1.5%). Discontinuations due to hyperkalemia or abnormal renal function were less than 1.0% in both groups.

###  Hypertension

Eplerenone has been evaluated for safety in 3091 patients treated for hypertension. A total of 690 patients were treated for over 6 months and 106 patients were treated for over 1 year.

In placebo-controlled studies, the overall rates of adverse events were 47% with eplerenone and 45% with placebo. Adverse events occurred at a similar rate regardless of age, gender, or race. Therapy was discontinued due to an adverse event in 3% of patients treated with eplerenone and 3% of patients given placebo. The most common reasons for discontinuation of eplerenone were headache, dizziness, angina pectoris/MI, and increased GGT.

Gynecomastia and abnormal vaginal bleeding were reported with eplerenone but not with placebo. The rates increased with increasing duration of therapy.
The present disclosure refers to topical pharmaceutical bases that include a synergistic combination of pracaxi oil, andiroba oil, copaiba balsam, and ucuuba butter. Further, these topical pharmaceutical bases are proposed for treating skin conditions in mammals, such as, for example wounds and scars. The topical pharmaceutical bases provide healing, moisturizing, anti-inflammatory, antibacterial, and antifungal effect. Additionally, the topical pharmaceutical bases enable an effective administration of specific active pharmaceutical ingredients (APIs), thereby improving treatment outcomes. Topical pharmaceutical compositions including the topical pharmaceutical bases increase the residence time of APIs within a wound or scar, thereby improving the penetration of APIs into the affected area. Also, the topical pharmaceutical bases provide relatively uniform distribution of the APIs within the topical pharmaceutical compositions. Further, the topical pharmaceutical compositions release APIs slowly, thereby enhancing treatment effectiveness.
Eribulin mesylate injection is supplied as a clear colorless solution in a clear glass vial, essentially free of visible foreign particulate matter. 

NDC 81298-3890-1 

Injection: 1 mg/2 mL, in a single-dose vial. One vial per carton. 

Store at 25°C (77°F); excursions permitted to 15° to 30° C (59° to 86° F). Do not freeze or refrigerate. Store the vials in their original cartons. 

Eribulin mesylate injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.¹
A method for computing the release rate of a controlled release drug and medical device using a combination of imaging data and computational physics is described. The method employs a three-dimensional digital representation of a drug sample, derived from two-dimensional or three-dimensional imaging, which captures the drug active pharmaceutical ingredient (API), excipients, and porosity with distinctive contrasts. Direct numerical simulations are conducted on the three-dimensional digital representation to derive effective transport properties of the API going through a porous matrix or membrane. Drug release rate can be predicted more efficiently than laboratory-based methods. When there is strong heterogeneity presented in the drug, a further method is described that engages imaging and release simulations at multiple scales. Computerized systems and programs for performing the methods are also described.
Chronic pain is usually a complex disorder with possible indications for an impairment at the personality functioning level. Guidelines recommend a multiprofessional interdisciplinary treatment approach. Based on the alternative model of personality disorders of the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) and the International Classification of Diseases, eleventh revision (ICD-11), an integrative manual was designed to exactly fit the interdisciplinary multimodal treatment of patients of the day clinic for pain at the orthopedic clinic of the University Hospital Heidelberg. The treatment manual specifically promotes various areas of personality functioning levels, such as emotion regulation, identity, empathy and relationships through individual and group interventions against the background of a mentalization-based therapeutic attitude. A focus group was used to qualitatively evaluate the implementation of the new treatment manual. With good applicability of the manual and satisfaction of the therapy team, a common language for the interdisciplinary team could be created to improve the therapeutic interaction.
Mitochondria are essential organelles because they generate the energy required for cellular functions. Kidney stones, as one of the most common urological diseases, have garnered significant attention. In this study, we first collected peripheral venous blood from patients with kidney stones and used qRT-PCR to detect mitochondrial DNA (mtDNA) copy number as a means of assessing mitochondrial function in these patients. Subsequently, through Western blotting, qPCR, immunofluorescence, immunohistochemistry, and transmission electron microscopy, we examined whether calcium oxalate crystals could cause mitochondrial dysfunction in the kidney in both in vitro and in vivo. We then examined the intersection of the DEGs obtained by transcriptome sequencing of the mouse kidney stone model with mitochondria-related genes, and performed KEGG and GO analyses on the intersecting genes. Finally, we administered the mitochondrial ROS scavenger Mito-Tempo in vivo and observed its effects. Our findings revealed that patients with kidney stones had a reduced mtDNA copy number in their peripheral venous blood compared to the control group, suggesting mitochondrial dysfunction in this population. This conclusion was further validated through in vitro and in vivo experiments. Enrichment analyses revealed that the intersecting genes were closely related to metabolism. We observed that after mitochondrial function was preserved, the deposition of calcium oxalate crystals decreased, and the kidney damage and inflammation caused by them were also alleviated. Our research indicates that kidney stones can cause mitochondrial dysfunction. After clearing mtROS, the damage and inflammation caused by kidney stones are reversed, providing new insights into the prevention and treatment of kidney stones.
There is a safety concern about a number of vaccine preservatives in use today, such as formaldehyde, phenol, organic mercury (thiomersal) or betapropiolactone for safety reasons. In a few vaccines, 2-phenoxyethanol has been used as a vaccine perservative, but has not gained widespread use, because the preservative effect is inferior to e.g. thiomersal. Applicant has found that the preservative effect of a mixture of 2-phenoxyethanol and para hydroxybenzoates, (e.g. methyl-, ethyl-, propyl- or butyl-, p-hydroxybenzoate) is more effective than 2-phenoxyethanol alone and that this mixture, called TF-1, exerts a preservative effect which is comparable to that of thiomersal or chloroform in vaccines. Although the preservative effect of TF-1 is satisfactory for securing the microbial stability of the vaccine, none of the constituents in TF-1 are considered as critical in terms of toxicity for the vaccinated animals or humans as chloroform or organic mercury compounds, traditionally used for the same purpose.
Breast infections are common, affect women of all ages, and are associated with significant morbidity. Despite overall prevalence, treatment varies significantly based on provider or institution and no central treatment guidelines exist to direct the management of breast infections. This article provides a summary of the current trends in management of breast infections. The etiology, epidemiology, risk factors, presentation, diagnosis, and treatment of mastitis and breast abscesses (and their relative subdivisions) are explored based on the current literature. Trends in microbiology are reviewed and an approach to antibiotic coverage is proposed. Overall, there is a lack of randomized-controlled trials focused on the treatment of breast infections. This has resulted in an absence of clinical practice guidelines for the management of breast abscesses and variable practice patterns. The development of best-care protocols or pathways could provide more uniformity in care of breast infections.
The pathogenesis of neuropathic pain (NP) is complex, and there are various pathological processes. Previous studies have suggested that lncRNA PCAT19 is abnormally expressed in NP conduction and affects the occurrence and development of pain. The aim of this study is to analyze the role and mechanism of PCAT19 in NP induced by chronic compressive nerve injury (CCI) in mice. In this study, C57BL/6 mice were applied to establish the CCI model. sh-PCAT19 was intrathecally injected once a day for 5 consecutive days from the second day after surgery. We discovered that PCat19 level was gradually up-regulated with the passage of modeling time. Downregulation of Iba-1-positive expression, M1/M2 ratio of microglia, and pro-inflammatory factors in the spinal cords of CCI-mice after PCat19 knock-downed was observed. Mechanically, the expression of miR-378a-3p was negatively correlated with KDM3A and PCat19. Deletion of KDM3A prevented H3K9me2 demethylation of BDNF promoter and suppressed BDNF expression. Further, KDM3A promotes CCI-induced neuroinflammation and microglia activation by mediating Brain-derived neurotrophic factor (BDNF) demethylation. Together, the results suggest that PCat19 may be involved in the development of NP and that PCat19 shRNA injection can attenuate microglia-induced neuroinflammation by blocking KDM3A-mediated demethylation of BDNF and BDNF release.
The invention discloses an application of Aminopothanola in preparing a medicine for treating lung adenocarcinoma, and belongs to the technical field of new medical application. The invention verifies the efficacy of Aminopotvalanola through in vitro experiments and in vivo experiments. In vitro experiments prove that the proliferation of the LUAD cell strain can be inhibited by the lower concentration of the AminopotivanolA drug. In vivo experiments prove that after the injection of the AminopotivanolA, the vital signs of the animals are stable, the acute poisoning symptoms are avoided, the tumor growth is effectively controlled, and the animals in the administration group have longer survival time. The AminopotrvalanolA has certain in vivo safety and effectiveness. Thus, aminopotrvalanolA has been shown to have potential for treating LUAD.
Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases . This feature vouches for a predictable pharmacokinetics and makes this drug suitable for administration in continuous intravenous infusion in order to achieve patient conscious sedation during non-invasive surgical procedures. Remifentanil could be particularly useful in day surgery setting, thanks also to its faster elimination than other oppioids. This property ensure a swift recovery from conscious sedation, reducing the period of time during which patient remains in recovery room and decreasing also the incidence of side effects, like PONV and respiratory depression. Conscious sedation with remifentanil can provide patient comfort and cooperation during surgical procedure, since the verbal contact with the patient is kept up. Extracorporeal shock wave lithotripsy (ESWL) is a non-invasive procedure, contemplated as the first-line treatment for renal and upper ureteral stones, if stone diameter is ranged from 5 to 20 mm . It can grind calculi into fine particles, that are expelled through micturition. Although many studies have been published in regard to continuous intravenous infusion of remifentanil, a small number of them focuses on which is the most appropriate infusion rate for ESWL procedure.
Second phase of the study. Cohort 2 will include the anti-PD1/L1 previously treated subpopulation.
The present invention relates to a cosmetic composition for improving skin elasticity and dermis density and reducing skin wrinkles, which contains an extract of Trachelospermum species or a fermented extract thereof. The extract of Trachelospermum species is an extract of at least one species selected from the group consisting of Trachelospermum asiaticum var. majus (Nakai) Ohwi, Trachelospermum jasminoides, Trachelospermum asiaticum, Trachelospermum asiaticum var. asiatica, Trachelospermum asiaticum var.variegatum, Trachelospermum asiaticum var. blanceolate, and Trachelospermum asiaticum var. intermedim.
EE-CTH seamlessly integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol specifically designed to enhance patient engagement in SMS activities. Key components of MI have been incorporated into a practical and systematic engagement protocol that includes: (1) acknowledging the patient's point of view; (2) identifying and labeling the patient's ambivalence (both the good reasons for making the change and the good reasons for not making the change); (3) evaluating whether change is really worth the effort; (4) identifying, reflecting and labeling accompanying feelings and concerns about change; and (5) establishing a small and meaningful goal by the end of the encounter.
In this review, current understanding of the prevention and treatment of Incontinence Associated Dermatitis (IAD) is discussed. The need for preventative measures which target specific faecal/urinary irritants is highlighted, including the role of urease inhibitors. There is no existing internationally and clinically accepted method to diagnose and categorise the severity of IAD. Diagnosis currently relies on visual inspection; non-invasive techniques to assess skin barrier function could remove subjectiveness, particularly in darker skin tones. Impedance spectroscopy is a non-invasive technique which can be used to monitor skin barrier function, supporting visual assessments. Six studies (2003-2021) which used impedance to assess dermatitis were reviewed; inflamed skin was distinguishable from healthy skin in each case. This suggests that impedance spectroscopy could be useful in diagnosis early-stage IAD, potentially enabling earlier intervention. Finally, the authors present their initial findings on the role of urease in skin breakdown in an in vivo IAD model, using impedance spectroscopy.
This is an open, nonrandomized, rising-dose study in patients with hormone refractory prostate cancer. Patients will be treated with L-377202 once every three weeks. Plasma concentrations of L-377202, liberated doxorubicin, and leu-doxorubicin will be obtained at defined time intervals throughout the study. At least 1 patient will be treated at each dose level until there is evidence of greater than or equal to Grade 2 drug-related toxicity. Each patient will be treated at only 1 dose level, although multiple cycles may be administered until signs of disease progression or unacceptable toxicity are evident. Doses will be doubled for each subsequent cohort of patients until evidence of greater than or equal to Grade 2 drug-related toxicity. Upon documentation of greater than or equal to Grade 2 drug-related toxicity, subsequent dose escalations will proceed along the modified Fibonacci scale and enroll at least 3 patients per dose level until 1 patient experiences dose-limiting toxicity (DLT).